On Nov 19, major Wall Street analysts update their ratings for $Syndax Pharmaceuticals (SNDX.US)$, with price targets ranging from $33 to $51.
Citi analyst Yigal Nochomovitz maintains with a buy rating, and adjusts the target price from $34 to $45.
Barclays analyst Peter Lawson maintains with a buy rating, and maintains the target price at $33.
TD Cowen analyst Phil Nadeau maintains with a buy rating.
Mizuho Securities analyst Salim Syed maintains with a buy rating.
H.C. Wainwright analyst Edward White maintains with a buy rating, and adjusts the target price from $49 to $51.
Furthermore, according to the comprehensive report, the opinions of $Syndax Pharmaceuticals (SNDX.US)$'s main analysts recently are as follows:
Following the FDA's approval of Revuforj, it's noted that prior concerns regarding the three-month extension were baseless. Additionally, the boxed warning for differentiation syndrome anticipated for Revuforj is likely to become standard across the broader menin-inhibitor class, representing no unique competitive disadvantage.
The company announced the FDA approval of REVUFORJ, revumenib, for relapsed or refractory acute leukemia with KMT2A translocation in adults and pediatric patients, which occurred 6-weeks before the expected PDUFA date. The safety and efficacy on the label align with expectations, and the recommendation for initial QTc monitoring during treatment is not seen as burdensome.
Here are the latest investment ratings and price targets for $Syndax Pharmaceuticals (SNDX.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月19日，多家華爾街大行更新了$Syndax Pharmaceuticals (SNDX.US)$的評級，目標價介於33美元至51美元。
花旗分析師Yigal Nochomovitz維持買入評級，並將目標價從34美元上調至45美元。
巴克萊銀行分析師Peter Lawson維持買入評級，維持目標價33美元。
TD Cowen分析師Phil Nadeau維持買入評級。
瑞穗證券分析師Salim Syed維持買入評級。
H.C. Wainwright分析師Edward White維持買入評級，並將目標價從49美元上調至51美元。
此外，綜合報道，$Syndax Pharmaceuticals (SNDX.US)$近期主要分析師觀點如下：
在FDA批准Revuforj之後，之前關於三個月延展的擔憂被認爲是毫無根據的。此外，預計Revuforj的分化綜合症的警告框將成爲更廣泛的毛蟲抑制劑類別中的標準，這並不會構成獨特的競爭劣勢。
公司宣佈FDA批准REVUFORJ（revumenib）用於成年和兒童患者中KMT2A易位的復發或難治性急性白血病，這一批准發生在預期的PDUFA日期前6周。標籤上的安全性和有效性與預期一致，首次在治療期間進行QTc監測的建議也並不被視爲負擔。
以下爲今日5位分析師對$Syndax Pharmaceuticals (SNDX.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
